Hypoglycaemia
inhibition of glycolysis and gluconeogenesis

Toxic effect on liver, kidney, small intestine

Fructose-1-phosphate

is accumulated

Dihydroxyacetone phosphate

Cleared by ALDOLASE B

Glyceraldehyde

Fructose-1-phosphate

Hypoglycaemia

Clinical symptoms of HFI

HFI is thus a fructose metabolic disorder which produces metabolites that are hepatotoxic and cause hypoglycaemia. Chronic exposure to the sugar can lead to an enlarged liver (hepatomegaly) and increasing liver failure. Infants often develop clinical symptoms after weaning and introduction of infant foods (which contain fructose). The symptoms can range from pronounced hypoglycaemia with vomiting, sweat attacks and neurological symptoms to cramps, lethargy and growth disorders. The infant often develops an aversion to sweet foods and fruit. This instinctive aversion means that HFI not uncommonly remains undetected until adulthood! Complete elimination of fructose is, however, hardly possible without diagnosis and precise dietary instructions because fructose is present in many types of vegetables in small quantities. This means that people with undiagnosed HFI often suffer from highly complex symptoms such as diarrhoea, abdominal pain and bloating and there is a risk of irreversible liver and kidney damage. As a distinguishing feature, such patients often have no caries.

Fig. The lack of aldolase B means that fructose-1-phosphate cannot be cleaved. This leads to an accumulation of the fructose-1-phosphate in the cells with a serious toxic effect. The elevated concentration of fructose-1-phosphate also inhibits glycolysis.

Symptoms of HFI

Acute exposure
Sweating
Shivering
Vomiting
Apathy
Cramps
Clothing disorders
Hypoglycaemia

Chronic exposure
Food aversion
Growth disorders
Restlessness – crying
Tympany
Hepatomegaly
Diarrhoea in some cases
Clothing disorder
Elevated transaminase
Oedema

HFI is caused by mutations in the aldolase B gene

Genetic variants in the aldolase B gene lead to an enzyme with a greatly reduced activity. The pathogenic mutations that are responsible for an aldolase B defect have been identified. The mutations A149P, A174D and N334K are the most common defects in Europe and are responsible for about 85 % of all patients with HFI. The remaining 15 % carry far rarer mutations in the aldolase B gene. HFI is an autosomal recessive disorder, that is, it manifests in patients who carry 2 mutations inherited on both the maternal and paternal allele. HFI has a frequency of about 1:20,000.

Diagnosis of HFI

The diagnosis of HFI is verified using molecular genetics. With suspected fructose intolerance, the three most common mutations (A149P, A174D, N334K) of the aldolase B gene are tested, by sequencing exon 5 and exon 9. If at least 2 mutations are found, HFI is considered proven. If, however, none of these more common mutations are detected, the probability of HFI is very low. If a single heterozygote mutation is present in the first test or in case of an urgent clinical suspicion, a search can be done in a second stage for additional, rarer mutations in the aldolase B gene.
**Material**

2 ml EDTA blood (an alternative is a buccal smear [children]). Transport to the laboratory is not time-sensitive and can be sent by mail.

**Invoicing**

2. stage analytic Exon 2, 3, 4, 6, 7, 8: 582.80 €

**Differentiation between HFI and fructose malabsorption**

In addition to a metabolic disorder, fructose transport problems can also cause fructose intolerance. This intolerance is known as fructose malabsorption in which fructose is only partially absorbed in the small intestine. This malabsorption can develop after damage to the epithelium of the small intestine as a result of HFI but can also manifest independently of HFI. Because in these cases measurable fructose metabolites end up in the lungs via the bloodstream, fructose malabsorption can be diagnosed using a fructose load test (H2 breath test).

However, before carrying out a fructose load test, HFI must first be ruled out (fructose intolerance genetic test) because a fructose load can lead to life-threatening metabolic crises in those affected.

**Therapy**

The only possible and successful treatment for HFI is to avoid fructose in the diet. In the case of babies and toddlers up to 2–3 years of age, the diet must be strictly adhered to. Tolerance of fructose may increase slightly as children become older, meaning that the intake of fructose can be slightly adapted on an individual basis. Systematically avoiding fructose with early diagnosis leads to a reduction in fatty liver. Differentiating between HFI and fructose malabsorption is very important for determining which treatment to use.

This is because HFI patients must eat a virtually fructose-free diet for life while for those patients with fructose malabsorption, a completely fructose-free diet leads to a deterioration in the long term because levels of the fructose transport molecules in the small intestine fall further. To treat fructose malabsorption, therefore, a fructose-modified diet with increased proportions of fat and protein is selected as this increases fructose absorption in the small intestine. It must also be remembered with fructose intolerance that many diabetic products, dietary supplements and low-calorie foods contain sorbitol. Because fructose is produced when sorbitol is broken down, eating such products exacerbates the symptoms.

**Literature**